Search press releases
Every release here is real and links to its original. Filter by company, topic, language and date.
- Roche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancerCompanies: Roche HoldingBasel, 13 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) today announced that its collaborator MediLink released interim results from the randomised phase III TAISHAN-302 trial evaluating Tam-Peli (tambotatug pelitecan, YL201) versus topotecan in Chinese patients with relapsed small-cell lung cancer (SCLC) who progressed after prior platinum-based chemotherapy with or without a PD-L1 inhibitor.1 The trial met its primary endpoint of overall survival (OS) with Tam-Peli demonstrating a statistically significant and clinically meaningful OS benefit, reducing the risk of death by 54% (median OS 13.3 vs. 9.4 months; stratified HR=0.46; p<0.0001). Tam-Peli also showed robust efficacy across secondary endpoints, significantly extending progression-free survival (PFS) (median PFS 7.4 vs. 2.8 months) and response rates (59.1% vs. 9.7%) compared to standard-of-care topotecan.1
- U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatmentsCompanies: Roche HoldingBasel, 10 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for Enspryng® (satralizumab) for the treatment of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). The filing acceptance is based on positive results from the Phase III METEOROID study, which showed that Enspryng provided consistent, clinically meaningful improvements for people living with MOGAD.1 This marks the second FDA Priority Review for Enspryng, following the one granted for thyroid eye disease (TED) in June 2026. The FDA is expected to make a decision on approval in MOGAD by 10 January 2027.
- Medication Adherence Global Market Report 2026-2035: Profiles Medtronic, Roche, Insulet, Ypsomed, and 13 Other Key PlayersCompanies: Medtronic plcInsuletRoche HoldingOpportunities include AI-enabled adherence platforms, connected inhalers, injectors and smart packaging, telehealth and home-care integration, chronic disease support, and pharmacy-led services in underserved and Asia-Pacific markets.
- Roche’s US subsidiary Genentech announces manufacturing expansion in the United StatesCompanies: Roche HoldingBasel, 20 August 2026 - Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY) today announced plans to invest approximately $750 million in a new device fill-finish manufacturing facility at its 75-acre campus in Hillsboro, Oregon. The investment will bring new end-to-end device filling capabilities to the site and expand capacity to support the future pipeline of innovative medicines across Roche and Genentech.